Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHerlev and Gentofte Hospital

About this trial

In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients 18 years or older with a diagnosis of psoriasis will be invited to participate

Disqualifiers

Patients not able to cooperate to the study

Patients unable understand and sign informed consent

Trial population

Psoriasis patients will be recruited prospectively from the Outpatient Clinic, Department of Dermato- Allergology, Herlev and Gentofte University Hospital, and Bispebjerg \& Frederiksberg Hospital, Denmark. Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: Psoriasis patients
Group B: Control group

Trial outcomes

Primary outcomes

1

Cardiovascular mortality

Time frame
2 year follow-up
2

Cardiovascular mortality

Time frame
5 year follow-up
3

Cardiovascular mortality

Time frame
10 year follow-up
4

Myocardial infarction

Time frame
2 year follow up

Secondary outcomes

1

All-cause mortality

Time frame
2 year follow up
2

All-cause mortality

Time frame
5 year follow up
3

All-cause mortality

Time frame
10 year follow up
4

Admission with cardiac heart failure (CHF)

Time frame
2 year follow up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.